Acute Myeloid Leukemia (non-APL) · line 2 · Olutasidenib monotherapy (Study 2102-HEM-101) — R/R AML with susceptible IDH1 mutation
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-OLUTASIDENIB-AML-RR-IDH1 |
| ID | IND-AML-RR-IDH1-OLUTASIDENIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | DIS-AML |
| Sources | SRC-ELN-AML-2022 SRC-ESMO-AML-2020 SRC-NCCN-AML-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L+ for R/R IDH1-mutated AML. Bridge-to-alloHCT intent dominant. Ukraine access constraint dominant (not registered; Rigel EAP / named-patient import only). Algorithm wiring deferred — not yet routed by ALGO-AML-2L step 5 (currently routes IDH1/IDH2 to ven+aza with MDT note); restructure required to swap step 5 to IND-AML-RR-IDH1-OLUTASIDENIB; out of chunk scope. Trial source SRC-OLUTASIDENIB-DEBOTTON-2023 available as a bibliographic record; pending KB ingestion.
Used By
No reverse references found in the YAML corpus.